Cargando…

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

SIMPLE SUMMARY: High grade neuroendocrine tumours and carcinomas (NETs/NECs) behave aggressively and have limited survival outcomes. The mainstay of therapy is systemic therapy, in which the associated side-effects are a key consideration in a palliative population. We have conducted a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelmalak, Rebecca, Lythgoe, Mark P., Evans, Joanne, Flynn, Michael, Waters, Justin, Webb, Andy, Pinato, David J., Sharma, Rohini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393440/ https://www.ncbi.nlm.nih.gov/pubmed/34439386 http://dx.doi.org/10.3390/cancers13164232

Ejemplares similares

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
por: Mollica, Veronica, et al.
Publicado: (2022)

Small cell neuroendocrine carcinoma with adenocarcinoma and high grade squamous intraepithelial neoplasia of the cervix
por: Gurubalan, Guralarasan, et al.
Publicado: (2023)

Preclinical Models of Neuroendocrine Neoplasia
por: Sedlack, Andrew J. H., et al.
Publicado: (2022)

ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs)
por: Sharma, Rohini, et al.
Publicado: (2022)

Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis
por: Bremer, Sebastian C. B., et al.
Publicado: (2022)

Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice
por: Luecke, Simone, et al.
Publicado: (2022)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia
por: Dizdar, Levent, et al.
Publicado: (2016)

Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer
por: Eisenach, P A, et al.
Publicado: (2013)

Gastric neuroendocrine neoplasias: manifestations and comparative outcomes
por: Felder, S, et al.
Publicado: (2019)

Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia
por: Maggio, Ilaria, et al.
Publicado: (2020)

Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
por: Papantoniou, Dimitrios, et al.
Publicado: (2020)

A Low-Grade Appendiceal Mucinous Neoplasia and Neuroendocrine Appendiceal Collision Tumor: A Case Report and Review of the Literature
por: Villa, Massimo, et al.
Publicado: (2021)

Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias
por: Albers, Max B., et al.
Publicado: (2020)

Prognostic Significance of Immunohistochemical Phenotypes in Patients Treated for High-Grade Cervical Intraepithelial Neoplasia
por: Origoni, Massimo, et al.
Publicado: (2013)

Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2
por: Saito, Mayumi, et al.
Publicado: (2022)

High-Grade Prostatic Intraepithelial Neoplasia
por: Klink, Joseph C, et al.
Publicado: (2012)

Biological Markers of Neoplasia
por: Vose, B. M.
Publicado: (1979)

Clinical characteristic and prognostic factors in high‐grade endometrial neuroendocrine carcinoma
por: Zhang, Zhifang, et al.
Publicado: (2022)

Management of Hepatocellular Cancer in the time of SARS‐CoV‐2
por: Sharma, Rohini, et al.
Publicado: (2020)

Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas
por: Wu, Yan, et al.
Publicado: (2021)

Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
por: Tonelli, Francesco, et al.
Publicado: (2012)

Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1
por: Marini, Francesca, et al.
Publicado: (2021)

Knife-assisted resection (KAR) for small rectal neuroendocrine neoplasia
por: Lisotti, Andrea, et al.
Publicado: (2020)

Pediatric Neuroendocrine Neoplasia of the Parathyroid Glands: Delving into Primary Hyperparathyroidism
por: Carsote, Mara, et al.
Publicado: (2023)

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3
por: Boers, A., et al.
Publicado: (2016)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy
por: Filosso, Pier Luigi, et al.
Publicado: (2020)

Microinvasion of High-Grade Pancreatic Intraepithelial Neoplasia
por: Kawada, Natsuko, et al.
Publicado: (2013)

Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review)
por: Ciobanu, Oana Alexandra, et al.
Publicado: (2021)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Markers for internal neoplasia in the horse
por: Drozdzewska, Karolina, et al.
Publicado: (2022)

Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin
por: Juhlin, Carl Christofer, et al.
Publicado: (2020)

Prognostic value of a three-scale grading system based on combining molecular imaging with (68)Ga-DOTATATE and (18)F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
por: Karfis, Ioannis, et al.
Publicado: (2020)

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age
por: Bongiovanni, Alberto, et al.
Publicado: (2018)

Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons
por: Bundschuh, Ralph A., et al.
Publicado: (2019)

Anxiety, Depression and Quality of Life in Patients with Neuroendocrine Neoplasia After Surgery
por: Begum, Nehara, et al.
Publicado: (2022)

Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1
por: Yliaska, Iina, et al.
Publicado: (2022)

Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
por: Marasco, Matteo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k189494glvn4o2hv54hastubfb